---
schema_version: "secwatch.filing_event.v1"
accession: "0000927066-22-000110"
form_type: "8-K"
ticker: "DVA"
cik: "0000927066"
company_name: "DAVITA INC."
filed_at: "2022-05-26T23:59:59+00:00"
generated_at: "2026-06-25T07:01:57.922077+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# DaVita and Medtronic form joint venture to create independent kidney-care device company

## Summary
- Equal equity stakes; Medtronic contributes Renal Care Solutions; DaVita pays $75M cash and $25M other assets.
- Each contributes $200M cash to launch NewCo; up to $300M milestone payments possible through 2028.
- Expected close in 2023, subject to HSR and other regulatory approvals.
- DaVita expects quarterly charges ~$20M after close, decreasing to zero in 2-3 years as NewCo reaches breakeven.
- Independent management and six-person board with two directors from each parent plus two independents.

## SEC filing metadata
- accession: 0000927066-22-000110
- form_type: 8-K
- ticker: DVA
- cik: 0000927066
- company_name: DAVITA INC.
- filed_at: 2022-05-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/927066/000092706622000110/0000927066-22-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/927066/000092706622000110/dva-20220525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000927066-22-000110
- JSON: https://secwatch.observer/filing/0000927066-22-000110.json
- Plain text: https://secwatch.observer/filing/0000927066-22-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.